Ningbo Menovo Pharmaceutical Co Ltd
SSE:603538
| US |
|
Fubotv Inc
NYSE:FUBO
|
Media
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
| US |
|
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
| CN |
|
NIO Inc
NYSE:NIO
|
Automobiles
|
| US |
|
Fluor Corp
NYSE:FLR
|
Construction
|
| US |
|
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
| US |
|
TopBuild Corp
NYSE:BLD
|
Consumer products
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
Health Care
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
| US |
|
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
| US |
|
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
| US |
|
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
| US |
|
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
| US |
|
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
10.01
21.01
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
|
|
Fubotv Inc
NYSE:FUBO
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
C
|
C3.ai Inc
NYSE:AI
|
US |
|
|
Uber Technologies Inc
NYSE:UBER
|
US |
|
|
NIO Inc
NYSE:NIO
|
CN |
|
|
Fluor Corp
NYSE:FLR
|
US |
|
|
Jacobs Engineering Group Inc
NYSE:J
|
US |
|
|
TopBuild Corp
NYSE:BLD
|
US |
|
|
Abbott Laboratories
NYSE:ABT
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
|
|
Occidental Petroleum Corp
NYSE:OXY
|
US |
|
|
Matrix Service Co
NASDAQ:MTRX
|
US |
|
|
Automatic Data Processing Inc
NASDAQ:ADP
|
US |
|
|
Qualcomm Inc
NASDAQ:QCOM
|
US |
|
|
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Ningbo Menovo Pharmaceutical Co Ltd
Research & Development
Ningbo Menovo Pharmaceutical Co Ltd
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
N
|
Ningbo Menovo Pharmaceutical Co Ltd
SSE:603538
|
Research & Development
-¥84.7m
|
CAGR 3-Years
-8%
|
CAGR 5-Years
-20%
|
CAGR 10-Years
N/A
|
|
|
H
|
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
|
Research & Development
-¥2.1B
|
CAGR 3-Years
-19%
|
CAGR 5-Years
-19%
|
CAGR 10-Years
N/A
|
|
|
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
|
Research & Development
-¥232.3m
|
CAGR 3-Years
-31%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
N/A
|
|
|
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
|
Research & Development
-¥5.8B
|
CAGR 3-Years
0%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
N/A
|
|
|
Yunnan Baiyao Group Co Ltd
SZSE:000538
|
Research & Development
-¥339.2m
|
CAGR 3-Years
-19%
|
CAGR 5-Years
-22%
|
CAGR 10-Years
N/A
|
|
|
S
|
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
|
Research & Development
-¥712.5m
|
CAGR 3-Years
-61%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Ningbo Menovo Pharmaceutical Co Ltd
Glance View
Ningbo Menovo Pharmaceutical Co., Ltd. engages in the research, development, testing, production, and sale of pharmaceutical products. The company is headquartered in Ningbo, Zhejiang and currently employs 2,473 full-time employees. The company went IPO on 2017-04-07. The Company’s products contain gastropathic medicine and cardiovascular medicine, which include anti-hypertension medicine, anti-hyperlipidemia medicine and anti-thrombus medicine. The firm distributes its products to both domestic and overseas markets.
See Also
What is Ningbo Menovo Pharmaceutical Co Ltd's Research & Development?
Research & Development
-84.7m
CNY
Based on the financial report for Dec 31, 2023, Ningbo Menovo Pharmaceutical Co Ltd's Research & Development amounts to -84.7m CNY.
What is Ningbo Menovo Pharmaceutical Co Ltd's Research & Development growth rate?
Research & Development CAGR 5Y
-20%
Over the last year, the Research & Development growth was -3%. The average annual Research & Development growth rates for Ningbo Menovo Pharmaceutical Co Ltd have been -8% over the past three years , -20% over the past five years .
You don't have any saved screeners yet
